Catalyst Wire Dossier Catalyst Wire Dossier

iCo-007

· iCo Therapeutics Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for iCo-007, covering 2012-03-22 to 2017-08-30. Get the full timeline:

Most recent: Clinical Trial Update: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) [Phase 2]

See pricing